Oragenics公司 (OGEN)

1.4300 +0.0500 (+3.65%) 市場開市。 截至 09:54AM EDT。

Oragenics公司

4902 Eisenhower Boulevard
Suite 125
Tampa, FL 33634
United States
813 286 7900
https://www.oragenics.com

版塊: Healthcare
行業: Biotechnology
全職員工: 5

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Charles L. Pope CPA	Executive Chairman	112.5k	無	1952
Mr. Joseph Michael Redmond	President & Interim Principal Executive Officer	無	無	1961
Ms. Janet Huffman	CFO, Secretary & Treasurer	314.9k	無	1972
Dr. James P. Kelly M.A., M.D.	Chief Medical Officer & Member of Scientific Advisor	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Oragenics, Inc., a development-stage company, engages in the research and development of nasal delivery pharmaceutical medications in neurology and fighting infectious diseases in the United States. Its lead product is ONP-002, a fully synthetic, non-naturally occurring neurosteroid which is lipophilic and can cross the blood-brain barrier to reduce swelling, oxidative stress, and inflammation while restoring proper blood flow through gene amplification. The company also develops NT-CoV2-1, a SARS-CoV-2 vaccine product candidate; and Lantibiotic Product Candidate, such as Mutacin 1140 (MU1140), a molecule belonging to the novel class of antibiotics. It has a license agreement with Inspirevax Inc. The company was formerly known as Oragen, Inc. Oragenics, Inc. was incorporated in 1996 and is headquartered in Tampa, Florida.

公司管治

截至 無 止，Oragenics公司 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。